Printer Friendly

Dyax Corp discloses early termination of Hart-Scott-Rodino waiting period on 2 December 2015.

M2 PHARMA-December 3, 2015-Dyax Corp discloses early termination of Hart-Scott-Rodino waiting period on 2 December 2015

(C)2015 M2 COMMUNICATIONS

Biopharmaceutical company Dyax (NasdaqGM:DYAX) reported on Wednesday the termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, for its planned acquisition by Shire Pharmaceuticals International (SPI), an indirect wholly-owned subsidiary of Shire.

The company said the Hart-Scott-Rodino Waiting Period was terminated by the United States Federal Trade Commission (FTC) on 2 December 2015.

Under the terms of a definitive merger agreement, SPI will acquire Dyax for USD37.30 in cash per Dyax share for aggregate upfront consideration of about USD5.9bn.

In conjunction, Dyax shareholders may receive additional value through a non-tradable contingent value right that will pay USD4.00 in cash per Dyax share upon approval of DX-2930 in hereditary angioedema (HAE), representing a potential additional USD646m in aggregate contingent consideration.

This merger remains subject to certain other closing conditions, including adoption of the merger agreement by Dyax's stockholders.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2015 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Dec 3, 2015
Words:178
Previous Article:AbbVie's NDA for once-daily formulation of VIEKIRA PAK accepted by the US FDA for treating patients with Genotype 1 Chronic Hepatitis C Virus.
Next Article:Delcath Systems announces completion of 250th CHEMOSAT treatment and start of the Harley Street Clinic.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters